Key result
GLP-1RAs and SGLT2is advance cardiovascular disease prevention in obesity, atherogenic dyslipidemia, and CKD.
Why the study?
Recent studies are advancing understanding of treatment options with GLP-1 receptor agonists and SGLT2 inhibitors in diabetes and metabolic disorders and related cardiovascular prevention.
A 2021 year-in-review summarizing the evolving role of GLP-1 receptor agonists and SGLT2 inhibitors in cardiovascular prevention for patients with metabolic disorders.
May inform metabolic CV prevention strategies; leaves open optimal integration pending dedicated RCTs.
In the current paper, we review recently published studies that are helping us to understand how the treatment landscape for glucagon-like peptiide-1 receptor agonists and sodium glucose cotransporter 2 inhibitors is moving forward. We have also included relevant articles related to cardiovascular disease prevention in the setting of obesity, atherogenic dyslipidaemia and chronic kidney disease.
No takes yet. Share an insight, caveat, or question.
Cosentino et al. (2021) studied this question. GLP-1 receptor agonists and SGLT2 inhibitors are advancing the treatment landscape for cardiovascular disease prevention in obesity, atherogenic dyslipidaemia, and chronic kidney disease.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: